Comparative analysis of patients with new onset refractory status epilepticus preceded by fever (febrile infection‐related epilepsy syndrome) versus without prior fever: An interim analysis
Anthony D. Jimenez,Margaret Gopaul,Hannah Asbell,Seyhmus Aydemir,Maysaa M. Basha,Ayush Batra,Charlotte Damien,Gregory S. Day,Onome Eka,Krista Eschbach,Safoora Fatima,Madeline C. Fields,Brandon Foreman,Elizabeth E. Gerard,Teneille E. Gofton,Hiba A. Haider,Stephen T. Hantus,Sara Hocker,Amy Jongeling,Mariel Kalkach Aparicio,Padmaja Kandula,Peter Kang,Karnig Kazazian,Marissa A. Kellogg,Minjee Kim,Jong Woo Lee,Lara V. Marcuse,Christopher M. McGraw,Wazim Mohamed,Janet Orozco,Cederic Pimentel,Vineet Punia,Alexandra M. Ramirez,Claude Steriade,Aaron F. Struck,Olga Taraschenko,Andrew K. Treister,Ji Yeoun Yoo,Sahar Zafar,Daniel J. Zhou,Deepti Zutshi,Nicolas Gaspard,Lawrence J. Hirsch,Aurelie Hanin
DOI: https://doi.org/10.1111/epi.17988
IF: 6.74
2024-04-17
Epilepsia
Abstract:Febrile infection‐related epilepsy syndrome (FIRES) is a subset of new onset refractory status epilepticus (NORSE) that involves a febrile infection prior to the onset of the refractory status epilepticus. It is unclear whether FIRES and non‐FIRES NORSE are distinct conditions. Here, we compare 34 patients with FIRES to 30 patients with non‐FIRES NORSE for demographics, clinical features, neuroimaging, and outcomes. Because patients with FIRES were younger than patients with non‐FIRES NORSE (median = 28 vs. 48 years old, p = .048) and more likely cryptogenic (odds ratio = 6.89), we next ran a regression analysis using age or etiology as a covariate. Respiratory and gastrointestinal prodromes occurred more frequently in FIRES patients, but no difference was found for non‐infection‐related prodromes. Status epilepticus subtype, cerebrospinal fluid (CSF) and magnetic resonance imaging findings, and outcomes were similar. However, FIRES cases were more frequently cryptogenic; had higher CSF interleukin 6, CSF macrophage inflammatory protein‐1 alpha (MIP‐1a), and serum chemokine ligand 2 (CCL2) levels; and received more antiseizure medications and immunotherapy. After controlling for age or etiology, no differences were observed in presenting symptoms and signs or inflammatory biomarkers, suggesting that FIRES and non‐FIRES NORSE are very similar conditions.
clinical neurology